Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Video Lectures

View video lectures on hot topics and challenging cases presented by world experts

The future for psoriasis pathogenesis & treatment

2019 Vienna, Austria
Peter van de Kerkhof, MD, PhD - The Netherlands


Pathogensis of psoriasis

2019 Vienna, Austria
Georg Stingl, MD - Austria



Precision medicine and biomarkers

Comorbidities 2020 Nick Reynolds, BSc, MBBS, MD, FRCP
Newcastle Upon Tyne, England, United Kingdom



Optimizing the use of biologics

Biologics 2019 Vienna, Austria
April Armstrong, MD - United States


Drug survival and the sequential use of biologics

Biologics 2019 EADV | Madrid, Spain
Lone Skov, MD, PhD – Denmark


A challenging case using various biologics

Biologics 2019 WCD | Milan, Italy
Lone Skov, MD, PhD – Denmark


News about psoriasis in Egypt

Biologics 2020 Mahira Hamdy El Sayed, Egypt
IPC Psoriasis Masterclass: Follow-up and Global Update | Virtual


Psoriasis updates in a nutshell

Biologics, Topical therapies 2020 Mohamed El-Komy, Egypt
2020 IPC Psoriasis Masterclass: Follow-up and Global Update | Virtual


Search Reviews:

Filter by Topic:

Latest news

February 08, 2021
Professor Francesca Capon provides a commentary An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%.
February 03, 2021
Dr. Ward is a Professor of Dermatology and Neurosciences at Case Western Reserve University and University Hospitals Case Medical Center in Cleveland, Ohio. She has spent the past 16 years developing mouse models to help identify the cellular and molecular mechanisms underlying inflammatory skin disease and its associated comorbidities.
February 02, 2021
n a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments. This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls. The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts. To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers.
January 28, 2021
IPC Academy Online, a free online learning platform, has been designed to provide expert insight, timely research, and practical information to dermatologists anywhere in the world to improve the care of psoriasis patients.
  More News
We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.